Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kyverna Therapeutics, Inc. - Common Stock (NQ:KYTX)

8.090 +0.680 (+9.18%)
Streaming Delayed Price Updated: 3:01 PM EDT, Jul 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 835,160
Open 7.550
Bid (Size) 8.090 (100)
Ask (Size) 8.100 (100)
Prev. Close 7.410
Today's Range 7.460 - 8.140
52wk Range 2.800 - 13.67
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel 
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
From Kyverna Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-7.8%
-7.8%
1 Month
-4.1%
-4.1%
3 Month
-10.0%
-10.0%
6 Month
-8.9%
-8.9%
1 Year
+86.8%
+86.8%

More News

Read More
News headline image
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Present at Upcoming Investor Conferences
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
News headline image
Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
From Kyverna Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Kyverna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Kyverna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Kyverna Therapeutics, Inc. - Common Stock trade on?
Kyverna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kyverna Therapeutics, Inc. - Common Stock?
The ticker symbol for Kyverna Therapeutics, Inc. - Common Stock is KYTX on the Nasdaq Stock Market
What is the current price of Kyverna Therapeutics, Inc. - Common Stock?
The current price of Kyverna Therapeutics, Inc. - Common Stock is 8.090
When was Kyverna Therapeutics, Inc. - Common Stock last traded?
The last trade of Kyverna Therapeutics, Inc. - Common Stock was at 07/27/26 03:01 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.